Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
EAACI biological guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis
Filename | 422. Agache et al., EAACI Biol GL - Dupi children and adults,Allergy2021.pdf |
Filesize | 2.09 MB |
Version | o.422 |
Date added | June 1, 2021 |
Downloaded | 0 times |
Category | Original Work |
Tags | atopic dermatitis, dupilumab, GRADE, Guideline |
Authors | Agache, I., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger T., Eyerich, K. Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O., and Jutel, M. |
Citation | Agache, I., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger T., Eyerich, K. Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O., and Jutel, M.: EAACI biological guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy 2021: 76; 988-1009. |
Corresponding authors | Agache, I. |
DocNum | o.422 |
DocType | |
IF | 14.71 |
Publisher | Allergy |
ReleaseDate | 2021 |
Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, com-plexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarifica-tion. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based), its cost-effectiveness and long-term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.
(Last update: 12.2023)
Number of original publications in peer-reviewed journals: | 580 |
Number of reviews in peer-reviewed journals: | 210 |
Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.